HIGH-THROUGHPUT SCREENING APPROACHES FOR IDENTIFICATION OF NEW BIOACTIVE COMPOUNDS
Keywords:
high-throughput screening; qHTS; phenotypic screening; high-content screening; bioactive compounds; DNA-encoded libraries; virtual screening; drug discoveryAbstract
High-throughput screening (HTS) remains a central technology for transforming large chemical collections into experimentally validated starting points for drug discovery. Modern screening has evolved from single-concentration biochemical assays toward quantitative concentration-response formats, multiparametric phenotypic imaging, DNA-encoded libraries, virtual screening, machine-learning prioritization, and human-relevant cellular models. This structured review evaluates contemporary HTS approaches used to identify new bioactive compounds and examines the methodological factors that determine hit quality, reproducibility, mechanistic interpretability, and translational value. Peer-reviewed international literature published between 1999 and 2025 was synthesized with emphasis on assay validation, quantitative HTS, phenotypic screening, high-content analysis, computational triage, DNA-encoded libraries, artifact control, and active-learning approaches. The evidence indicates that no single platform is optimal for all discovery programs. Robust campaigns increasingly combine complementary technologies: biochemically precise primary assays, dose-response confirmation, orthogonal and counter screens, phenotypic profiling, cheminformatic filters, and early developability assessment. Z′-factor and control-based quality metrics remain fundamental, but modern screening quality also depends on concentration-response behavior, chemical tractability, assay-interference control, and reproducibility across orthogonal systems. Recent integration of omics and active learning can substantially enrich hit rates in complex phenotypic campaigns. The most effective strategy is therefore an integrated screening cascade that balances scale with biological relevance and uses explicit quality gates before compounds advance to hit-to-lead optimization.
References
1. Macarron, R., Banks, M. N., Bojanic, D., et al. (2011). Impact of high-throughput screening in biomedical research. Nature Reviews Drug Discovery, 10, 188-195. https://doi.org/10.1038/nrd3368
2. Inglese, J., Auld, D. S., Jadhav, A., Johnson, R. L., Simeonov, A., Yasgar, A., Zheng, W., & Austin, C. P. (2006). Quantitative high-throughput screening: A titration-based approach that efficiently identifies biological activities in large chemical libraries. Proceedings of the National Academy of Sciences USA, 103(31), 11473-11478. https://doi.org/10.1073/pnas.0604348103
3. Zhang, J. H., Chung, T. D. Y., & Oldenburg, K. R. (1999). A simple statistical parameter for use in evaluation and validation of high throughput screening assays. Journal of Biomolecular Screening, 4(2), 67-73. https://doi.org/10.1177/108705719900400206
4. Swinney, D. C., & Anthony, J. (2011). How were new medicines discovered? Nature Reviews Drug Discovery, 10, 507-519. https://doi.org/10.1038/nrd3480
5. Vincent, F., Nueda, A., Lee, J., et al. (2022). Phenotypic drug discovery: Recent successes, lessons learned and new directions. Nature Reviews Drug Discovery, 21, 899-914. https://doi.org/10.1038/s41573-022-00472-w
6. Moffat, J. G., Vincent, F., Lee, J. A., Eder, J., & Prunotto, M. (2017). Opportunities and challenges in phenotypic drug discovery: An industry perspective. Nature Reviews Drug Discovery, 16, 531-543. https://doi.org/10.1038/nrd.2017.111
7. Caicedo, J. C., Cooper, S., Heigwer, F., et al. (2017). Data-analysis strategies for image-based cell profiling. Nature Methods, 14, 849-863. https://doi.org/10.1038/nmeth.4397
8. Peterson, A. A., & Liu, D. R. (2023). Small-molecule discovery through DNA-encoded libraries. Nature Reviews Drug Discovery, 22, 699-722. https://doi.org/10.1038/s41573-023-00713-6
9. Bajorath, J. (2002). Integration of virtual and high-throughput screening. Nature Reviews Drug Discovery, 1, 882-894. https://doi.org/10.1038/nrd941
10. Walters, W. P., & Namchuk, M. (2003). Designing screens: How to make your hits a hit. Nature Reviews Drug Discovery, 2, 259-266. https://doi.org/10.1038/nrd1063
11. Baell, J. B., & Holloway, G. A. (2010). New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. Journal of Medicinal Chemistry, 53(7), 2719-2740. https://doi.org/10.1021/jm901137j
12. Shoichet, B. K. (2006). Interpreting steep dose-response curves in early inhibitor discovery. Journal of Medicinal Chemistry, 49(25), 7274-7277. https://doi.org/10.1021/jm061103g
13. Bray, M. A., & Carpenter, A. E. (2017). Advanced assay development guidelines for image-based high content screening and analysis. In: Assay Guidance Manual. Bethesda, MD: Eli Lilly & Company and the National Center for Advancing Translational Sciences.
14. DeMeo, B., Nesbitt, C., Miller, S. A., et al. (2025). Active learning framework leveraging transcriptomics identifies modulators of disease phenotypes. Science, 390(6776), eadi8577. https://doi.org/10.1126/science.adi8577
